Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nervgen Pharma Corp (NGEN.VN)

Nervgen Pharma Corp (NGEN.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange GlobeNewswire - Thu Mar 12, 3:15PM CDT

The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs GlobeNewswire - Wed Mar 4, 6:30AM CST

VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
Upcoming Meeting Dates - February 23, 2026 Newsfile - Sun Feb 22, 11:06PM CST

Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...

ELD.TO : 45.78 (-3.92%)
SCD.VN : 0.155 (unch)
STE.VN : 0.450 (-8.16%)
WPRT.TO : 2.57 (+0.78%)
GMTN.VN : 1.830 (-4.94%)
WGO.VN : 1.480 (-6.33%)
ISGI.VN : 0.010 (unch)
SLF.TO : 86.65 (-0.10%)
VGZ.TO : 2.51 (-9.71%)
ARX.TO : 28.96 (-1.56%)
WPM.TO : 164.95 (-2.70%)
CRI.VN : 0.110 (-15.38%)
NervGen Pharma to Participate at Upcoming Investor Conferences GlobeNewswire - Wed Feb 18, 6:30AM CST

VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams GlobeNewswire - Thu Feb 12, 3:15PM CST

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium GlobeNewswire - Wed Feb 11, 6:00AM CST

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence,...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury GlobeNewswire - Mon Feb 9, 6:00AM CST

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing GlobeNewswire - Tue Jan 20, 6:00AM CST

VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Begins Trading on Nasdaq Today GlobeNewswire - Thu Jan 8, 5:30AM CST

VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...

NGEN : 3.66 (-6.39%)
NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS Newsfile - Wed Dec 17, 2025

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing...

NGENF : 5.8400 (+5.23%)
NGEN.VN : 5.150 (+3.00%)

Barchart Exclusives

The General Mills Dividend Yields 6.53%. Is That Enough to Make Up for an Oil Price Shock? Barchart - Thu Mar 26, 6:30PM CDT
General Mills’ high 6.53% dividend yield may look enticing, but it comes amid falling earnings, rising oil-driven cost pressures, and growing macro risks that could limit upside. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.